Literature DB >> 7737072

Programmed therapeutic messages as a smoking treatment adjunct: reducing the impact of negative affect.

T H Brandon1, A L Copeland, Z L Saper.   

Abstract

Maintaining treatment gains remains a challenge to smoking cessation programs. Smokers prone to negative affect are most likely to relapse. In an effort to improve maintenance, a standard cognitive-behavioral treatment was supplemented with the provision of computer-controlled audiotape players containing personalized therapeutic messages. Either the standard treatment alone, or the standard treatment plus 2 months use of the tape player were provided to 41 smokers. No outcome difference was found between the 2 conditions during the 1-year follow-up. (The combined 1-year abstinence rate was 61%, with 34% continuously abstinent.) The frequency with which participants used the device predicted both posttreatment coping skill use and smoking rate. Most notable was an interaction between treatment condition and negative affect. Provision of the devices negated or reversed the usual association between negative affect and poorer outcome.

Entities:  

Mesh:

Year:  1995        PMID: 7737072     DOI: 10.1037//0278-6133.14.1.41

Source DB:  PubMed          Journal:  Health Psychol        ISSN: 0278-6133            Impact factor:   4.267


  19 in total

1.  Do daily interactive voice response reports of smoking behavior correspond with retrospective reports?

Authors:  Benjamin A Toll; Ned L Cooney; Sherry A McKee; Stephanie S O'Malley
Journal:  Psychol Addict Behav       Date:  2005-09

2.  Decline in cue-provoked craving during cue exposure therapy for smoking cessation.

Authors:  Marina Unrod; David J Drobes; Paul R Stasiewicz; Joseph W Ditre; Bryan Heckman; Ralph R Miller; Steven K Sutton; Thomas H Brandon
Journal:  Nicotine Tob Res       Date:  2013-09-28       Impact factor: 4.244

3.  LINKING SESSION FOCUS TO TREATMENT OUTCOME IN EVIDENCE-BASED TREATMENTS FOR ADOLESCENT SUBSTANCE ABUSE.

Authors:  Aaron Hogue; Sarah Dauber; Howard A Liddle; Jessica Samuolis
Journal:  Psychotherapy (Chic)       Date:  2004

4.  Maternal cocaine use and caregiving status: group differences in caregiver and infant risk variables.

Authors:  Rina D Eiden; Audra Foote; Pamela Schuetze
Journal:  Addict Behav       Date:  2006-07-11       Impact factor: 3.913

5.  Cue exposure and response prevention with heavy smokers: a laboratory-based randomised placebo-controlled trial examining the effects of D-cycloserine on cue reactivity and attentional bias.

Authors:  Sunjeev K Kamboj; Alyssa Joye; Ravi K Das; Andrew J W Gibson; Celia J A Morgan; H Valerie Curran
Journal:  Psychopharmacology (Berl)       Date:  2011-11-22       Impact factor: 4.530

6.  The association between maternal cocaine use during pregnancy and physiological regulation in 4- to 8-week-old infants: an examination of possible mediators and moderators.

Authors:  Pamela Schuetze; Rina D Eiden
Journal:  J Pediatr Psychol       Date:  2005-03-23

7.  Effects of prenatal cocaine exposure on infant reactivity and regulation.

Authors:  Rina D Eiden; Shannon McAuliffe; Lorig Kachadourian; Claire Coles; Craig Colder; Pamela Schuetze
Journal:  Neurotoxicol Teratol       Date:  2008-09-10       Impact factor: 3.763

8.  Conceptual model for maternal behavior among polydrug cocaine-using mothers: the role of postnatal cocaine use and maternal depression.

Authors:  Rina D Eiden; Arianne Stevens; Pamela Schuetze; Laura E Dombkowski
Journal:  Psychol Addict Behav       Date:  2006-03

9.  Profiles of Reactivity in Cocaine-Exposed Children.

Authors:  Pamela Schuetze; Danielle S Molnar; Rina D Eiden
Journal:  J Appl Dev Psychol       Date:  2012-10-11

10.  Effects of sequential fluoxetine and gender on prequit depressive symptoms, affect, craving, and quit day abstinence in smokers with elevated depressive symptoms: a growth curve modeling approach.

Authors:  Haruka Minami; Christopher W Kahler; Erika Litvin Bloom; Mark A Prince; Ana M Abrantes; David R Strong; Raymond Niaura; Ivan W Miller; Kathleen M Palm Reed; Lawrence H Price; Richard A Brown
Journal:  Exp Clin Psychopharmacol       Date:  2014-08-04       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.